Soma has not been proven to have a specific mechanism of action for reducing pain and suffering brought on by acute musculoskeletal disorders. According to research done on animal models, the spinal cord’s and the brain’s descending reticular formation’s interneuronal activity changes when carisoprodol causes muscles to relax. The central nervous system (CNS) is the primary target of the centrally acting skeletal muscle relaxant carisoprodol, which does not directly affect skeletal muscle.